Free Trial

Legend Biotech (LEGN) Stock Price, News & Analysis

$41.41
+1.91 (+4.84%)
(As of 05/24/2024 ET)
Today's Range
$39.55
$42.12
50-Day Range
$39.50
$64.66
52-Week Range
$39.13
$77.32
Volume
1.63 million shs
Average Volume
984,989 shs
Market Capitalization
$7.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.10

Legend Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
95.8% Upside
$81.10 Price Target
Short Interest
Bearish
7.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of Legend Biotech in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.84) to ($0.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars

Medical Sector

460th out of 917 stocks

Biotechnology Industry

13th out of 35 stocks

LEGN stock logo

About Legend Biotech Stock (NASDAQ:LEGN)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

LEGN Stock Price History

LEGN Stock News Headlines

Legend Biotech (NASDAQ:LEGN) PT Raised to $86.00
Q1 2024 Legend Biotech Corp Earnings Call
Legend Biotech Vaults on Quarterlies
See More Headlines
Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/13/2024
Today
5/25/2024
Next Earnings (Estimated)
8/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:LEGN
Fax
N/A
Employees
2,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$81.10
High Stock Price Target
$94.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+95.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-518,250,000.00
Net Margins
-135.92%
Pretax Margin
-182.41%

Debt

Sales & Book Value

Annual Sales
$285.14 million
Book Value
$6.39 per share

Miscellaneous

Free Float
182,247,000
Market Cap
$7.55 billion
Optionable
Optionable
Beta
0.12
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Ying Huang Ph.D. (Age 51)
    CEO & Director
  • Ms. Lori A. Macomber CPA (Age 53)
    Chief Financial Officer
  • Mr. Doug Wallace
    Vice President of Global Operations
  • Dr. Guowei Fang Ph.D.
    Chief Scientific Officer & Head of Business Development
  • Joanne Choi
    Senior Manager of Investor Relations
  • Mr. James Pepin J.D.
    General Counsel
  • Deborah Wong
    Executive Director of Strategic Marketing & Corporate Communications
  • Ms. Elaine Qian
    VP & Global Head of Human Resources
  • Dr. Yuhong Qiu Ph.D.
    Senior Vice President of Global Regulatory Affairs
  • Mr. Steven J. Gavel
    Senior Vice President of Commercial Development, US & Europe

LEGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LEGN shares.
View LEGN analyst ratings
or view top-rated stocks.

What is Legend Biotech's stock price target for 2024?

11 analysts have issued 1 year price targets for Legend Biotech's stock. Their LEGN share price targets range from $60.00 to $94.00. On average, they predict the company's stock price to reach $81.10 in the next twelve months. This suggests a possible upside of 95.8% from the stock's current price.
View analysts price targets for LEGN
or view top-rated stocks among Wall Street analysts.

How have LEGN shares performed in 2024?

Legend Biotech's stock was trading at $60.17 at the beginning of 2024. Since then, LEGN stock has decreased by 31.2% and is now trading at $41.41.
View the best growth stocks for 2024 here
.

When is Legend Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024.
View our LEGN earnings forecast
.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) announced its quarterly earnings results on Monday, May, 13th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.13. The company had revenue of $93.90 million for the quarter, compared to analyst estimates of $143.24 million. Legend Biotech had a negative trailing twelve-month return on equity of 27.91% and a negative net margin of 135.92%. The firm's revenue was up 158.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.40) earnings per share.

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?

Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO.

Who are Legend Biotech's major shareholders?

Legend Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.02%), RA Capital Management L.P. (3.77%), Westfield Capital Management Co. LP (1.23%), Capital International Investors (1.20%), Janus Henderson Group PLC (1.11%) and TimesSquare Capital Management LLC (0.64%).

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LEGN) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners